BC’s Kardium raises $115 million USD for heart device technology
Kardium, a British Columbia-based medical device company, has secured $115 million USD from Fidelity Management and T. Rowe Price Associates.
The round was led by United States-based Fidelity Management, with T. Rowe Price Associates providing follow-on investment after leading Kardium’s $40 million USD financing in 2018.
The company is reportedly looking to hit the public markets in 2024.
Kardium is a medical tech company that has developed a device that treats atrial fibrillation, a common heart disorder rate that can increase the risk of strokes, heart failure and other heart-related complications. The company’s Globe Mapping and Ablation System is considered an advanced system for the treatment of atrial fibrillation.